Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Go back to Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.80 +0.40 (2.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.40 | 52 Week High | $5.58 | |||
| Open | $14.77 | 52 Week Low | $3.60 | |||
| Day High | $14.85 | P/E | N/A | |||
| Day Low | $14.69 | EPS | $0.00 | |||
| Volume | 5,698,924 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 43.17 +0.58 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.59 | 52 Week High | $44.76 | |||
| Open | $42.82 | 52 Week Low | $36.81 | |||
| Day High | $43.23 | P/E | N/A | |||
| Day Low | $42.82 | EPS | $0.00 | |||
| Volume | 2,762,507 | |||||
